STOCK TITAN

Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Insight Molecular Diagnostics (Nasdaq: IMDX) priced an underwritten public offering expected to raise approximately $15 million in gross proceeds.

The offering comprises 8,296,429 common shares at $1.75 each and pre-funded warrants to purchase up to 275,000 shares at $1.7499 per warrant, with a $0.0001 per-share exercise price. The underwriter has a 30-day option to purchase up to 1,285,714 additional shares. Closing is expected on or about November 18, 2026. Gross proceeds exclude underwriting discounts, commissions and other offering expenses. Planned uses include working capital and general corporate purposes, including transplantation research and development.

Loading...
Loading translation...
2 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.Approximately $15 million in expected gross proceeds would provide funding before underwriting discounts, commissions and other offering expenses. 25% of market cap
  • Minor point. Forward-looking: it has not happened yet and may not happen.Transplantation research and development is among the company's intended uses of net proceeds.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.8,296,429 common shares at $1.75 each will dilute existing holders.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Pre-funded warrants for up to 275,000 shares add dilution at $1.7499 each plus a $0.0001 per-share exercise price.
  • Minor point. Forward-looking: it has not happened yet and may not happen.30-day underwriter option permits up to 1,285,714 additional shares at the public offering price, less underwriting discounts and commissions.

News Explained

The expected $15 million gross raise equals 214.5 days of third-quarter operating cash use, before offering costs.

iMDx has priced but not closed the offering; it is selling the securities itself, and shares issued in the offering, including shares from any warrant exercise, would increase the share count and reduce existing holders’ percentage ownership.

The pre-funded warrants are sold at nearly the full common-share price with a nominal exercise price and convert to shares when exercised.

At the third-quarter 2026 operating-cash-outflow rate, the expected $15 million gross proceeds equal 214.5 days of that past cash use, based on reported outflow of $6.433 million; the figure is before offering costs.

Sources and calculations
  • Offering gross against the last reported quarterly operating outflow, in days at that rate $15,000,000 / ($6,433,000 / 92) = 214.5 days

Key Figures

Common shares offered: 8,296,429 shares Common share offering price: $1.75 per share Pre-funded warrants: Up to 275,000 at $1.7499 each +3 more
Common shares offered
8,296,429 shares
At $1.75 per share
Common share offering price
$1.75 per share
Public offering
Pre-funded warrants
Up to 275,000 at $1.7499 each
Each warrant has a $0.0001 per-share exercise price
Underwriter option
Up to 1,285,714 shares
30-day option at the public offering price, less underwriting discounts and commissions
Expected gross proceeds
Approximately $15 million
Before underwriting discounts, commissions, and other offering expenses
Expected offering close
On or about November 18, 2026
Subject to customary closing conditions

Key Terms

pre-funded warrants, underwritten public offering, shelf registration statement, prospectus supplement
4 terms
pre-funded warrants financial
"pre-funded warrants to purchase up to 275,000 shares of common stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
underwritten public offering financial
"pricing of its underwritten public offering"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
shelf registration statement regulatory
"A shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"by means of a prospectus supplement and accompanying prospectus"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NASHVILLE, Tenn., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced the pricing of its underwritten public offering of 8,296,429 shares of its common stock at a price to the public of $1.75 per share and pre-funded warrants to purchase up to 275,000 shares of common stock at a price to the public of $1.7499 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants in the offering are being sold by iMDx. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 1,285,714 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to the Company from the offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about November 18, 2026, subject to customary closing conditions.

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including but not limited to research and development in the transplantation category.

Lake Street Capital Markets is acting as the sole managing underwriter for the offering.

A shelf registration statement on Form S-3 (File No. 333-281159) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and has been declared effective. The offering is being made only by means of a prospectus supplement and accompanying prospectus. A copy of the final prospectus supplement and an accompany prospectus related to the offering, when available, can be obtained for free by visiting the SEC’s website at http://www.sec.gov or by contacting: Lake Street Capital Markets, LLC, 121 South 8th Street, Suite 1000, Minneapolis, MN 55402, by telephone at (612) 326-1305 or e-mail at syndicate@lakestreetcm.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.

GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as “estimates,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These statements include those pertaining to the consummation of the offering and the satisfaction of customary closing conditions related to the offering and the use of proceeds therefrom. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, the risk that the FDA may not accept our response to its request for additional information, may request further information, or may not grant marketing authorization for GraftAssureDx on the expected timeline or at all, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Insight Molecular Diagnostics’ third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third-party reimbursement for patients’ use of any diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other cautionary statements found in Insight Molecular Diagnostics’ SEC filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.  

Investor Contact:

Alexandra Grossman
LifeSci Advisors LLC
imdx@lifesciadvisors.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much will Insight Molecular Diagnostics raise in its IMDX public offering, and at what price?

Insight Molecular Diagnostics expects approximately $15 million in gross proceeds before underwriting discounts, commissions and other offering expenses. The offering includes 8,296,429 common shares at $1.75 each and pre-funded warrants for up to 275,000 shares at $1.7499 per warrant, with a $0.0001 per-share exercise price.

When is Insight Molecular Diagnostics expected to close its public offering?

Insight Molecular Diagnostics expects the offering to close on or about November 18, 2026, subject to customary closing conditions.

Keep reading